| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 22.06. | Regeneron's New Drug Application for cemdisiran accepted for review by FDA and EMA | ||
| 22.06. | Sanofi appoints Paulo Fontoura as Global Head of R&D | ||
| 18.06. | Sanofi's Sarclisa approved by MHRA as UK's first anti-cancer treatment given via on-body injector | ||
| 18.06. | Pfizer appoints Cecile Guegan as Interim CFO | ||
| 17.06. | Takeda's new study data for oveporexton shows improvements in narcolepsy type 1 | ||
| 17.06. | Broken String Biosciences appoints Bruce Eaton as Chairman of the Board | ||
| 16.06. | Bridging the gap between European brain innovation and real-world policy | ||
| 16.06. | Gilead's New Drug Application for Yeztugo accepted by US FDA | ||
| 15.06. | Ultomiris gets US FDA Priority Review for immunoglobulin A nephropathy treatment | ||
| 15.06. | Fondazione Telethon appoints Graciana Diez-Roux as new Scientific Director | ||
| 12.06. | Novo Nordisk's Wegovy approved as UK's first daily GLP-1 weight loss pill | ||
| 12.06. | Obesity care in the UK - why it can't improve until it is recognised as a disease | ||
| 11.06. | Roche's Tecentriq gets FDA Priority Review for specific stage 3 colon cancer | ||
| 11.06. | Oriva Therapeutics appoints Agnès Arbat as CEO | ||
| 10.06. | Lilly's Ebglyss approved by FDA as maintenance dose for atopic dermatitis | ||
| 10.06. | The next frontier in clinical trials: navigating multi-disease research with GLP-1s | ||
| 09.06. | CSL's Privigen approved as measles treatment by European Commission | ||
| 09.06. | GSK to acquire biopharma Nuvalent for $10.6bn | ||
| 08.06. | Roche and Nurix Therapeutics to partner in $2.3bn deal | ||
| 08.06. | Headline trade and market deals are opening doors to greater patient access | ||
| 05.06. | Biogen's salanersen gets FDA Breakthrough Therapy Designation for SMA | ||
| 05.06. | Men's health: the gap between awareness and action is where men's lives are lost | ||
| 04.06. | Alnylam and Inceptive agree on $2bn AI collaboration | ||
| 04.06. | Ardena appoints Ariane de Ganck as Chief Scientific Officer | ||
| 03.06. | Bristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate |